3 minute read
Feb. 9, 2022

PF-07321332: an Oral, Reversible Covalent SARS-CoV-2 Main Protease Inhibitor

Pfizer CoV-2 MPro Inhibitor

oral pan-coronavirus antiviral, rev. covalent Ph. III candidate for COVID-19 (300 mg BID) from SARS-CoV-1 inhibitor (WO2005113580) paxlovid (PF-07321332) Pfizer Worldwide Research

Drug Hunter Team

Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which received emergency use authorization from the FDA for Covid treatment at the end of 2021. Clinical data showed Paxlovid reducing Covid hospitalization and death by 89%. It was nominated for November’s cover by Mike Koehler [...]



Other molecules you may be interested in